What Is the Best Treatment for Grover’s Disease?

Topical corticosteroids are the most commonly used treatment for Grover’s disease and are generally recommended as first-line therapy, with a response rate of about 70 percent in published cases.¹ Beyond that straightforward answer, though, the picture gets complicated quickly. No standardized treatment protocol exists, the disease ranges from a mild annoyance that disappears on its own to a stubborn, intensely itchy condition lasting years, and several other therapies from oral retinoids to biologics have shown promise when steroid creams fall short.

What Grover’s Disease Actually Is

Grover’s disease, formally called transient acantholytic dermatosis, shows up as small, itchy, red bumps and tiny blisters that cluster mainly on the trunk. Under a microscope, the hallmark is acantholysis, a breakdown of the connections between skin cells that creates small clefts in the upper layers of the skin. The condition can mimic several different skin diseases histologically: a review of 72 biopsy-confirmed cases found that the most common pattern resembled pemphigus vulgaris (about 56 percent of cases), followed by patterns resembling Darier’s disease, spongiotic dermatitis, and Hailey-Hailey disease.² These different microscopic patterns are part of why treatment can be unpredictable; what looks like one disease clinically can involve more than one underlying process in the skin.

The word “transient” in the formal name is a bit misleading. While many cases do resolve within weeks to months, some patients deal with persistent or recurrent flares for years. Quality of life can take a real hit, particularly from the relentless itching, and the lack of a standardized approach to treatment means patients and dermatologists often end up working through several options before finding something that helps.³

Who Gets It and What Triggers It

Grover’s disease overwhelmingly affects middle-aged and older adults, with the average patient in their mid-sixties and men outnumbering women roughly two to one.⁴ That said, cases have been reported in patients as young as 14.⁵

The triggers are telling, because understanding them shapes the non-drug side of treatment. Heat and sweating are the most consistent provocateurs. Case reports have traced flares to hot tubs, electric blankets, steam baths, prolonged bed confinement after surgery, and even the sustained wearing of non-breathable polyester clothing.⁶ Sun exposure is another recognized trigger. More recently, both SARS-CoV-2 infection and COVID-19 vaccination have been linked to Grover-like eruptions, though these remain isolated reports rather than a common pattern.⁷

A separate and important trigger category is medication, especially chemotherapy. In a systematic review of extensive or atypical Grover’s disease, about 61 percent of patients had a history of malignancy, and roughly 38 percent had recently received chemotherapy.⁵ The drug-triggered form deserves separate attention, since managing it sometimes means adjusting the medication rather than simply adding a topical cream on top.

Topical Corticosteroids and Vitamin D Analogues

For most people who walk into a dermatologist’s office with Grover’s disease, treatment starts with a medium- to high-potency topical corticosteroid applied to the affected areas. A systematic review found that topical corticosteroids were the most frequently used treatment across published literature, with about a 70 percent response rate.¹ Triamcinolone acetonide 0.1% cream is a typical choice, usually applied for a couple of weeks.⁸ Because the trunk is the most common site, patients are generally dealing with a broad area, which limits how long potent steroids can be safely used due to skin thinning.

Topical vitamin D analogues, particularly calcipotriol ointment, represent a steroid-sparing alternative. One early report documented significant clinical improvement after just three weeks of calcipotriol as a standalone treatment.⁹ Review articles now list vitamin D analogues alongside topical steroids as first-line therapy.¹⁰ In practice, some dermatologists alternate between the two or use them in combination, reserving the steroid for active flares and the vitamin D analogue for maintenance.

Antihistamines are commonly added alongside topical treatments, not because they address the underlying skin changes, but because the itching can be severe enough to disrupt sleep and daily life. Oral antihistamines are considered adjuvant therapy rather than a standalone treatment.¹⁰ Over-the-counter emollients and anti-itch creams tend to offer only minimal relief on their own.⁸

Oral Retinoids for Stubborn Cases

When topical treatments fail to clear the rash or the disease keeps coming back, systemic retinoids are the next step that dermatologists most often reach for. The same systematic review that placed topical steroids as first-line found that systemic retinoids had a higher response rate, about 86 percent, though they were used less frequently.¹ That higher success rate is tempered by the fact that retinoids tend to be reserved for more severe cases, so the populations aren’t directly comparable. Still, the evidence is encouraging enough that low-dose oral isotretinoin has become a go-to for refractory Grover’s disease.

A case series specifically focused on refractory disease reported clearance with low-dose isotretinoin in patients who had previously failed multiple other treatments.¹¹ “Low-dose” is key here. The doses used for Grover’s disease are typically lower than what’s prescribed for severe acne, which reduces side effects like dry lips, joint pain, and the blood-lipid changes that retinoids can cause. That said, isotretinoin still requires monitoring through blood tests and is absolutely off-limits during pregnancy.

Systemic corticosteroids (oral prednisone, for instance) also have a role, with a response rate of roughly 64 percent in the systematic review data.¹ They work faster than retinoids and can tamp down a severe flare quickly, but the well-known side effects of systemic steroids make them a poor choice for long-term management. Most dermatologists use short courses to bring a bad flare under control, then transition to something else for maintenance.

Phototherapy and Its Contradictions

Light-based therapies occupy a paradoxical space in Grover’s disease. On one hand, UV exposure is a recognized trigger. On the other hand, controlled phototherapy has been tried as a treatment, and in some forms it seems to help. A nonrandomized controlled trial investigated blue light phototherapy for Grover’s disease and reported no treatment-related adverse events.¹² Blue light sits at a different part of the spectrum than the UV wavelengths typically associated with triggering the disease, which may explain why it’s better tolerated.

PUVA therapy, which combines a photosensitizing drug (psoralen) with UVA light, has been listed among treatment options for Grover’s disease in various review articles. However, at least one well-documented case showed the opposite effect: a patient’s lesions worsened significantly after five sessions of PUVA, with generalized redness and aggravation of the rash, forcing the treatment to be stopped.¹³ The authors cautioned that because UV exposure itself can trigger Grover’s disease, phototherapy must be approached carefully, with early reassessment. If the rash is getting worse rather than better after a few sessions, it’s time to stop.

This contradiction reflects a broader truth about managing Grover’s disease: the same intervention can help one patient and harm another, and there’s currently no reliable way to predict which outcome you’ll get. Close follow-up matters more with phototherapy than with most other options.

Dupilumab and the Biologic Frontier

For patients who have cycled through topical steroids, retinoids, and other conventional approaches without lasting relief, newer biologic therapies represent a genuinely exciting development. Dupilumab, a monoclonal antibody already approved for atopic dermatitis and several other inflammatory conditions, has shown promise in resistant Grover’s disease. One published case described a patient who achieved complete resolution of her rash and symptoms by the sixth injection, after a loading dose followed by biweekly maintenance injections. She remained in remission for at least 11 months on continued treatment.¹⁴

Research published in the British Journal of Dermatology has added a mechanistic rationale for why dupilumab works: Grover’s disease appears to involve type 2 immune activation, the same immune pathway dupilumab targets.¹⁵ This is more than just an isolated success story; it suggests that Grover’s disease, at least in some patients, shares underlying biology with conditions like eczema. That shared biology could open the door to other medications in the same class.

Dupilumab is currently used off-label for Grover’s disease, meaning it isn’t specifically approved for this condition. It’s expensive without insurance coverage for an approved indication, and it requires ongoing injections. For now, it sits firmly in the “tried everything else” category. But as more case reports and small studies accumulate, it may move earlier in the treatment sequence for patients with severe or persistent disease.

When Chemotherapy Is the Cause

Drug-triggered Grover’s disease, particularly from chemotherapy, requires a somewhat different management mindset. Among the chemotherapy agents most commonly linked to Grover’s disease are cytotoxic drugs like cytarabine, daunorubicin, and etoposide, as well as newer targeted therapies and immunotherapy drugs such as ipilimumab, vemurafenib, and dabrafenib.¹⁶ One proposed mechanism is that the drug accumulates in the eccrine sweat glands and then leaks into surrounding skin, disrupting the connections between cells.¹⁶

In this setting, the primary treatment question becomes whether the offending drug can be paused, switched, or dose-adjusted without compromising cancer treatment. That’s a decision between the oncologist and the dermatologist, and it depends heavily on the patient’s cancer type, available alternatives, and how severely the skin disease is affecting their daily life. Supportive care with topical steroids and antihistamines can help manage symptoms while these decisions are being made. A review in the Journal of Drugs in Dermatology noted that chemotherapy-associated Grover’s disease is reported most frequently with cytotoxic chemotherapies, followed by small molecule inhibitors.¹⁷

If the cancer drug cannot be changed, the same ladder of treatments applies: topical steroids first, then oral retinoids or systemic steroids if needed. Some oncology patients also have immune suppression that limits which treatments are safe, adding another layer of complexity.

Lifestyle Measures and Trigger Avoidance

Because Grover’s disease tends to be provoked or worsened by heat and sweating, non-drug strategies are an important part of management. Since the disease tends to resolve on its own in many cases, prevention-focused measures can sometimes be enough for mild disease.¹⁰ Practical steps include:

• Stay cool: Air conditioning, loose-fitting breathable clothing, and avoiding prolonged hot environments can reduce flares. Cases have been traced to hot tubs, electric blankets, and steam baths.⁶
• Manage sweating: If you exercise regularly, showering promptly afterward and wearing moisture-wicking fabrics may help. Prolonged sweating in any context is a recognized trigger.¹⁸
• Sun protection: Since UV exposure can both trigger the disease and complicate phototherapy-based treatments, reasonable sun protection is sensible during active flares.
• Moisturize: While emollients alone tend not to control the rash, keeping the skin barrier intact may reduce irritation and the urge to scratch, which can worsen lesions.

These measures won’t cure persistent Grover’s disease, but they can reduce the frequency and severity of flares, and for patients with mild or truly transient disease, they may be sufficient on their own.

Why Getting a Biopsy Matters

One practical point worth emphasizing: Grover’s disease can look like many other conditions to the naked eye, including eczema, folliculitis, and various drug rashes. A skin biopsy showing the characteristic suprabasilar and intraspinous acantholysis is what confirms the diagnosis.¹⁹ This matters for treatment because the therapies that work for Grover’s disease are not the same ones that work for the conditions it mimics. A patient incorrectly treated for eczema with moisturizers and mild steroids might not get better, while someone correctly diagnosed can be started on the right potency of topical steroid or referred for retinoid therapy sooner.

Newer diagnostic tools may help clinicians spot the disease more accurately. A recent study found that a technique called sub-ultraviolet reflectance dermoscopy could detect characteristic features of Grover’s disease, including eccrine duct involvement in over 76 percent of images, which was superior to conventional dermoscopy for identifying certain hallmark signs.²⁰ These tools are unlikely to replace biopsy as the gold standard anytime soon, but they could help dermatologists decide which suspicious lesions to biopsy in the first place.

Radiotherapy as a Last Resort

For the small number of patients whose disease resists every conventional treatment, there is one more option in the literature: total skin electron beam radiotherapy. This is about as aggressive as treatment gets for a benign skin condition, and it reflects how profoundly persistent Grover’s disease can affect someone’s quality of life. A published case report described successful treatment of recalcitrant Grover’s disease with this modality, believed to be the first such reported use.³ Electron beam radiotherapy delivers radiation only to the superficial layers of the skin, sparing deeper tissues, but it still carries risks including skin dryness, pigmentation changes, and long-term concerns about secondary skin cancers. It is reserved for patients who have failed multiple lines of therapy and whose symptoms are severe enough to justify the risks. Most patients with Grover’s disease will never need to consider it, but its existence in the literature is a reminder that dermatologists do have escalation options for truly refractory cases.